This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

CSL Behring Announces The 2014 Interlaken Leadership Awards Recipient

Stocks in this article: CSL

KING OF PRUSSIA, Pa., June 24, 2014 /PRNewswire/ --  CSL Behring announced today that Bart C. Jacobs, M.D., Ph.D., Erasmus University Medical Center, Rotterdam, Netherlands, is the recipient of the 2014 Interlaken Leadership Awards for original research in the field of neuroimmunology. Established in 2010, this annual global awards program provides monetary grants and/or product supply for investigational use to researchers whose proposals are likely to advance innovative medical research and knowledge about the potential role of immunoglobulin (Ig) therapy in the treatment of neurological disorders.

A global, cross-functional CSL Behring review committee selected Dr. Jacobs' proposal to investigate the efficacy of intravenous immunoglobulin (IVIg) treatment in patients with mild Guillain-Barre syndrome (GBS). GBS is an inflammatory disorder of the peripheral nerves characterized by the rapid onset of weakness and, often, paralysis of the legs, arms, breathing muscles and face. While IVIg is recommended in severe GBS, current guidelines recommend providing supportive care only to those with mild forms of GBS. 

"Recent studies have demonstrated that a considerable proportion of untreated patients with mild Guillain-Barre syndrome have persistent disability, severe residual fatigue and pain, and poor quality of life, and my hypotheses is that IVIg may improve disease in these patients," said Dr. Jacobs. "I am honored to have been selected by CSL Behring to receive the Interlaken Leadership Award, and look forward to continuing research into whether IVIg may improve outcomes for those with mild GBS."

All proposals received for the Interlaken Leadership Awards program were evaluated based on scientific merit, strength of hypothesis, relevance to neuroimmunology and feasibility.

"The Interlaken Leadership Awards underpins CSL Behring's commitment to saving lives and improving the quality of life for people with rare and serious diseases worldwide by funding innovative research that could lead to the discovery of new treatment options for people who are living with a neurological disorder," said Bernadine Dixon, Senior Director, Immunology and Pulmonary, CSL Behring. "We look forward to the results of Dr. Jacobs' research evaluating the potential use of IVIg for treatment of mild Guillain-Barre syndrome, as well as to supporting further original research in the field of neuroimmunology through the Interlaken Leadership Awards."

To date, the Interlaken Leadership Awards has awarded approximately $3.5 million in grants and/or study drug for research studying Ig therapy in areas such as neuromyelitis optica (NMO), Duchenne muscular dystrophy (DMD), complex regional pain syndrome (CRPS), paraneoplastic syndromes, and autoimmune peripheral neuropathies.

About the International Immunoglobulin Conference in InterlakenFor more than three decades, CSL Behring has sponsored a high-level scientific symposium in Interlaken, Switzerland. First held in 1981, and most recently in April 2014, the International Immunoglobulin Conference focuses exclusively on scientific and clinical research in the field of polyvalent immunoglobulins.

Research presented at the Interlaken Immunoglobulin Conference is consistently at the forefront of immunoglobulin research. Since its inception, the conference has won the respect and support of top international scientists and clinicians from many different fields of research. For more information, please visit: http://www.interlakenleadershipawards.com/symposium.aspx.

About CSL BehringCSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit http://www.cslbehring.com/.

Media Contact: Greg HealySenior Manager, Public Relations & CommunicationsCSL Behring1-610-878-4841 greg.healy@cslbehring.com

SOURCE CSL Behring

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs